Description

Buy ADB-FUBINACA online

ADB-FUBINACA is a designer drug identified in synthetic cannabis blends in Japan in 2013. The enantiomer of ADB-FUBINACA is claimed in Pfizer patent WO 2009/106982. However, it has been reported to be potent. Also, it is an agonist of the CB₁ receptor and CB₂ receptor with an EC₅₀ value of 1.2 nM and 3.5 nM respectively. It is a very popular cannabinoid.

Metabolism Of ADB-FUBINACA

Twenty-three ADB-FUBINACA major metabolites were identified in several incubations with cryopreserved human hepatocytes. However, the major metabolic pathways were alkyl and indazole hydroxylation, terminal amide hydrolysis, subsequent glucuronide conjugations, and dehydrogenation.